Xilio Therapeutics (XLO) Cash from Investing Activities (2020 - 2026)

Xilio Therapeutics has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$556000.0 for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$556000.0, down 2427.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 2743.24% YoY), and the FY2025 annual result was -$518000.0, down 1338.89% from the prior year.
• Cash from Investing Activities came in at -$556000.0 for Q1 2026 at Xilio Therapeutics, down from -$95000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$6000.0 in Q4 2024 to a low of -$771000.0 in Q2 2022.
• The 5-year median for Cash from Investing Activities is -$285000.0 (2022), against an average of -$286833.3.
• Across the five-year window, Cash from Investing Activities soared 59.01% in 2023 and tumbled 2427.27% in 2026, its largest moves.
• Xilio Therapeutics' Cash from Investing Activities stood at -$509000.0 in 2022, then surged by 37.92% to -$316000.0 in 2023, then surged by 98.1% to -$6000.0 in 2024, then sank by 1483.33% to -$95000.0 in 2025, then plunged by 485.26% to -$556000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$556000.0 (Q1 2026), -$95000.0 (Q4 2025), and -$401000.0 (Q2 2025), per Business Quant data.